Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer.

ABSTRACT:

Background

Data on exposure-response or exposure-toxicity relationships of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are limited and inconclusive. We aimed to investigate whether there is an association between palbociclib exposure and progression-free survival (PFS), adverse events (AEs) and dose reductions.

Materials and methods

Data were retrieved from the prospective, multicentre SONIA trial in which patients with advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer were randomised to receive CDK4/6i treatment in first versus second line. Blood for pharmacokinetics (PK) was taken at day 15 of cycles 1 and 2 during CDK4/6i treatment. Individual trough concentrations and plasma area under the curves of palbociclib were

SUBMITTER: Buijs SM 

PROVIDER: S-EPMC11872518 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature